Acta Med. 2018, 61: 86-92

https://doi.org/10.14712/18059694.2018.123

Soluble Tumor Necrosis Factor (TNF)-Like Weak Inducer of Apoptosis (Tweak) Independently Predicts Subclinical Atherosclerosis in Behcet’s Disease

Abdullah Iclia, Medine Cumhur Cureb, Erkan Curec, Sevket Arsland, Mehmet Unale, Davut Sakizf, Miyase Ozucang, Aysun Tokerh, Kultigin Turkmeni, Adem Kucukj

aDepartment of Cardiology, Necmettin Erbakan University, Konya, Turkey
bDepartment of Biochemistry, Istanbul Laboratory, Istanbul, Turkey
cDepartment of Internal Medicine, Camlica Erdem Hospital, Istanbul, Turkey
dDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey
eDepartment of Dermatology, Konya Numune Hospital, Konya, Turkey
fDivision of Endocrinology, Department of Internal Medicine, Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
gDepartment of Internal Medicine, Necmettin Erbakan University, Konya, Turkey
hDepartment of Biochemistry, Necmettin Erbakan University, Konya, Turkey
iDivision of Nephrology, Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey
jDivision of Rheumatology, Department of Internal Medicine, Malatya State Hospital, Malatya, Turkey

Received May 25, 2018
Accepted September 25, 2018

References

1. Butta NV, Fernandez-Bello I, Lopez-Longo FJ, Jimenez-Yuste V. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behçet Disease. Semin Thromb Hemost 2015; 41: 621–8.
2. Atzeni F, Sarzi-Puttini P, Doria A, Boiardi L, Pipitone N, Salvarani C. Behçet’s disease and cardiovascular involvement. Lupus 2005; 14: 723–6. <https://doi.org/10.1191/0961203305lu2208oa>
3. Ulusan Z, Karadag AS, Tasar M, Kalender M, Darcin OT. Behcet’s disease and cardiovascular involvement: our experience of asymptomatic Behcet’s patients. Cardiovasc J Afr 2014; 25: 63–6. <https://doi.org/10.5830/CVJA-2014-003> <PubMed>
4. Merashli M, Ster IC, Ames PR. Subclinical atherosclerosis in Behcet’s disease: A systematic review and meta-analysis. Semin Arthritis Rheum 2016; 45: 502–10. <https://doi.org/10.1016/j.semarthrit.2015.06.018>
5. Yuksel M, Yildiz A, Oylumlu M, et al. Novel markers of endothelial dysfunction and inflammation in Behçet’s disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio. Clin Rheumatol 2016; 35: 701–8. <https://doi.org/10.1007/s10067-015-2907-0>
6. Maecker H, Varfolomeev E, Kischkel F, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005; 123: 931–44. <https://doi.org/10.1016/j.cell.2005.09.022>
7. Novoyatleva T, Sajjad A, Engel FB. TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure. Front Immunol 2014; 5: 50. <https://doi.org/10.3389/fimmu.2014.00050> <PubMed>
8. Desplat-Jego S, Creidy R, Varriale S, et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 2005; 117: 15–23. <https://doi.org/10.1016/j.clim.2005.06.005>
9. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/ Fn14 pathway in health and disease. Cytokine 2007; 40: 1–16. <https://doi.org/10.1016/j.cyto.2007.09.007>
10. Bertin D, Stephan D, Khrestchatisky M, Desplat-Jego S. Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases? Front Immunol 2013; 4: 489. <https://doi.org/10.3389/fimmu.2013.00489> <PubMed>
11. Vendrell J, Chacon MR. TWEAK: A New Player in Obesity and Diabetes. Front Immunol 2013; 4: 488. <https://doi.org/10.3389/fimmu.2013.00488> <PubMed>
12. Blanco-Colio LM, Martín-Ventura JL, Munoz-Garcia B, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 916–22. <https://doi.org/10.1161/01.ATV.0000258972.10109.ff>
13. Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 1990; 335: 1078–80.
14. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38: 728–33. <https://doi.org/10.1093/rheumatology/38.8.728>
15. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 2001; 12(11): 2458–64.
16. Wang C, Chen LL, Pan HF, Leng RX, Qin WZ, Ye DQ. Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus. Clin Rheumatol 2012; 31(2): 335–9.4. <https://doi.org/10.1007/s10067-011-1865-4>
17. Park MC, Chung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2008; 37: 173–8. <https://doi.org/10.1080/03009740801898608>
18. Xia L, Shen H, Xiao W, Lu J. Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase- 3 serum levels. Cytokine 2011; 53: 289–91. <https://doi.org/10.1016/j.cyto.2010.12.003>
19. Liu ZC, Zhou QL, Li XZ, et al. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Cytokine 2011; 53: 295–300. <https://doi.org/10.1016/j.cyto.2010.11.012>
20. Dharmapatni AA, Smith MD, Crotti TN, et al. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther 2011; 13: R51. <https://doi.org/10.1186/ar3294> <PubMed>
21. Chen T, Guo ZP, Li L, et al. TWEAK enhances E-selectin and ICAM- 1 expression, and may contribute to the development of cutaneous vasculitis. PLoS One 2013; 8: e56830. <https://doi.org/10.1371/journal.pone.0056830> <PubMed>
22. Bielecki M, Kowal K, Lapinska A, et al. Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. Folia Histochem Cytobiol 2009; 47: 465–9. <https://doi.org/10.2478/v10042-010-0028-9>
23. Evereklioglu C, Er H, Türköz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediators Inflamm 2002; 11: 87–93. <https://doi.org/10.1080/09629350220131935> <PubMed>
24. Hassan SB, El-demery AB, Ahmed AI, Abukhalil RE. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients. Arab J Nephrol Transplant 2012; 5: 27–32.
25. Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/ Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004; 9: 2273–84. <https://doi.org/10.2741/1395>
26. Kim SH, Kang YJ, Kim WJ, et al. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004; 68: 396–9. <https://doi.org/10.1253/circj.68.396>
27. Gungor O, Kismali E, Sisman AR, et al. The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients. Ren Fail 2013; 35: 77–81. <https://doi.org/10.3109/0886022X.2012.734890>
28. Turkmen K, Tonbul HZ, Erdur FM, et al. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol 2013; 14: 144. <https://doi.org/10.1186/1471-2369-14-144> <PubMed>
29. Azak A, Akdoğan MF, Denizli N, et al. Soluble TWEAK levels are independently associated with coronary artery disease severity in patients with stage 2–3 kidney disease. Int Urol Nephrol 2014; 46: 411–5. <https://doi.org/10.1007/s11255-013-0562-4>
30. Vazquez-Carballo A, Ceperuelo-Mallafre V, Chacon MR, et al. TWEAK prevents TNF-α-induced insulin resistance through PP2A activation in human adipocytes. Am J Physiol Endocrinol Metab 2013; 305: E101–12. <https://doi.org/10.1152/ajpendo.00589.2012>
31. Simon-Muela I, Llaurado G, Chacon MR, et al. Reduced circulating levels of TWEAK are associated with gestational diabetes mellitus. Eur J Clin Invest 2015; 45: 27–35. <https://doi.org/10.1111/eci.12375>
32. Kralisch S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008; 199: 440–4. <https://doi.org/10.1016/j.atherosclerosis.2007.10.022>
33. Blanco-Colio LM, Martín-Ventura JL, Munoz-Garcia B, et al. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci 2007; 12: 3648–55. <https://doi.org/10.2741/2341>
34. Li H, Mittal A, Paul PK, et al. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J Biol Chem 2009; 284: 4439–50. <https://doi.org/10.1074/jbc.M805546200> <PubMed>
35. Wako M, Ohba T, Ando T, et al. Mechanism of signal transduction in tumor necrosis factor-like weak inducer of apoptosis-induced matrix degradation by MMP-3 upregulation in disc tissues. Spine (Phila Pa 1976) 2008; 33: 2489–94. <https://doi.org/10.1097/BRS.0b013e318186b343>
36. Munoz-Garcia B, Madrigal-Matute J, Moreno JA, et al. TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res 2011; 89: 225–33. <https://doi.org/10.1093/cvr/cvq278>
37. Blanco-Colio LM. TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. Front Immunol 2014; 5: 3. <https://doi.org/10.3389/fimmu.2014.00003> <PubMed>
38. Messedi M, Frigui M, Ben Mahfoudh K, et al. Intima-media thickness of carotid artery in patients with Behçet’s disease. Arch Med Res 2011; 42: 398–404. <https://doi.org/10.1016/j.arcmed.2011.08.006>
39. Ozturk C, Balta S, Balta I, et al. Neutrophil-lymphocyte ratio and carotid- intima media thickness in patients with Behçet disease without cardiovascular involvement. Angiology 2015; 66: 291–6. <https://doi.org/10.1177/0003319714527638>
40. Ferreira JP, Girerd N, Bozec E, et al. Intima-Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Population-Based Cohort (STANISLAS Cohort Study). J Am Heart Assoc 2016; 5: e003529. <https://doi.org/10.1161/JAHA.116.003529> <PubMed>
41. Leonardo NM, McNeil J. Behcet’s Disease: Is There Geographical Variation? A Review Far from the Silk Road. Int J Rheumatol 2015; 2015: 945262.
42. Müftüoğlu AU, Yazici H, Yurdakul S, et al. Behçet’s disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986; 25: 235–9. <https://doi.org/10.1111/j.1365-4362.1986.tb02232.x>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive